Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) shares dropped 4% during trading on Monday . The stock traded as low as $30.80 and last traded at $30.80, with a volume of 715,845 shares. The stock had previously closed at $32.10.

ALDR has been the subject of several research analyst reports. Brean Capital initiated coverage on Alder BioPharmaceuticals in a research note on Wednesday, April 20th. They set a “buy” rating and a $45.00 target price for the company. Jefferies Group reiterated a “buy” rating on shares of Alder BioPharmaceuticals in a research note on Thursday, June 30th. Zacks Investment Research downgraded Alder BioPharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, June 28th. Finally, Wells Fargo & Co. began coverage on Alder BioPharmaceuticals in a research note on Thursday, April 21st. They issued an “outperform” rating for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $47.60.

The stock’s market capitalization is $1.55 billion. The stock’s 50 day moving average is $26.87 and its 200-day moving average is $25.20.

Alder BioPharmaceuticals (NASDAQ:ALDR) last issued its quarterly earnings data on Tuesday, July 26th. The biopharmaceutical company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by $0.04. The company earned $0.11 million during the quarter, compared to analyst estimates of $1.14 million. The firm’s revenue was up 112900.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.46) EPS. Analysts predict that Alder BioPharmaceuticals Inc. will post ($2.76) earnings per share for the current fiscal year.

In related news, insider Mark James Litton sold 6,000 shares of the stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $28.94, for a total transaction of $173,640.00. Following the completion of the sale, the insider now directly owns 74,567 shares of the company’s stock, valued at $2,157,968.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Randall C. Schatzman sold 10,000 shares of the stock in a transaction that occurred on Tuesday, May 24th. The shares were sold at an average price of $28.02, for a total value of $280,200.00. Following the sale, the chief executive officer now directly owns 115,933 shares of the company’s stock, valued at $3,248,442.66. The disclosure for this sale can be found here.

A number of institutional investors have recently made changes to their positions in ALDR. Pyrrho Capital Management LP raised its position in shares of Alder BioPharmaceuticals by 205.0% in the fourth quarter. Pyrrho Capital Management LP now owns 63,000 shares of the biopharmaceutical company’s stock valued at $2,081,000 after buying an additional 42,343 shares during the period. Wells Fargo & Company MN raised its position in shares of Alder BioPharmaceuticals by 290.6% in the fourth quarter. Wells Fargo & Company MN now owns 269,774 shares of the biopharmaceutical company’s stock valued at $8,911,000 after buying an additional 200,707 shares during the period. ProShare Advisors LLC raised its position in shares of Alder BioPharmaceuticals by 8.6% in the fourth quarter. ProShare Advisors LLC now owns 38,476 shares of the biopharmaceutical company’s stock valued at $1,271,000 after buying an additional 3,058 shares during the period. California Public Employees Retirement System raised its position in shares of Alder BioPharmaceuticals by 834.5% in the fourth quarter. California Public Employees Retirement System now owns 81,300 shares of the biopharmaceutical company’s stock valued at $2,685,000 after buying an additional 72,600 shares during the period. Finally, Nationwide Fund Advisors raised its position in shares of Alder BioPharmaceuticals by 103.6% in the fourth quarter. Nationwide Fund Advisors now owns 30,380 shares of the biopharmaceutical company’s stock valued at $1,003,000 after buying an additional 15,457 shares during the period.

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.